Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 3/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.55 |
| ▸ | ITGAL | P20701 | 2/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.55 |
| ▸ | PTGFR | P43088 | 2/20 | 0.55 |
| ▸ | PTGIR | P43119 | 2/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406682 | 1.00 | PTGER3 (0.55) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL7378645 | 1.00 | PTGER3 (0.55) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL481451 | 0.85 | MAPT (0.65) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL165227 | 0.85 | MAPT (0.65) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL29419102 | 0.85 | MAPT (0.65) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL1674366 | 0.83 | MIF (0.54) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL7687333 | 0.83 | MAPT (0.46) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL7687335 | 0.83 | MAPT (0.46) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| Hydrochloric Acid SCHEMBL6822024 | 0.83 | MAPT (0.63) | PTGER3PTGER2MAPTITGB2ICAM1 | |
| SCHEMBL11459860 | 0.83 | MAPT (0.63) | PTGER3PTGER2MAPTITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930859-A | Cinnamic acid modified polyarylene sulfide and preparation method thereof | 新凝合科技(成都)有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-118930859-A | Cinnamic acid modified polyarylene sulfide and preparation method thereof | 新凝合科技(成都)有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-116768792-B | Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof | 浙江工业大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| CN-117343072-A | 1-substituted cinnamoyl-2-oxo lycorine compound and preparation method and application thereof | 山东达因海洋生物制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116768792-A | Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof | 浙江工业大学 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023000398-A1 | LYCORINE β-ARYL ACRYLATE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东达因海洋生物制药股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| CN-110156703-B | Phenazine derivatives as TrxR1 inhibitors, intermediates, and methods of making and using the same | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-113416199-B | Lycorine beta-aryl acrylate derivative and preparation method and application thereof | 山东达因海洋生物制药股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113416199-A | Lycorine beta-aryl acrylate derivative and preparation method and application thereof | 山东达因海洋生物制药股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-112876365-A | Methyl rupestonic acid derivative containing cinnamoyl and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2021-06-01 | — | — | CN | disclosed |
| CN-110156703-A | As the phenazene derivative of TrxR1 inhibitor, intermediate product and its preparation method and application | 中国药科大学 | 2019-08-23 | — | — | CN | disclosed |
| US-9204652-B2 | Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2622960-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | Central Glass Company, Limited (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| WO-1997023202-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | SEM1, CD81, VMA21 | PTGER3 4820/4885PTGER2 4628/4885MAPT 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.